Perioperative THR-184 and AKI after Cardiac Surgery

• Published in: Journal of the American Society of Nephrology Vol. 29; no. 2; pp. 670 - 679
• Main Authors: Himmelfarb, Jonathan, Chertow, Glenn M, McCullough, Peter A, Mesana, Thierry, Shaw, Andrew D, Sundt, Thoralf M, Brown, Craig, Cortville, David, Dagenais, François, de Varennes, Benoit, Fontes, Manuel, Rossert, Jerome, Tardif, Jean-Claude
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 01.02.2018
• Subjects: Acute Kidney Injury - etiology; Acute Kidney Injury - physiopathology; Acute Kidney Injury - prevention & control; Aged; Aged, 80 and over; Bone Morphogenetic Protein 7 - agonists; Cardiac Surgical Procedures - adverse effects; Clinical Research; Double-Blind Method; Female; Humans; Male; Middle Aged; Perioperative Period; Severity of Illness Index; Treatment Failure; randomized controlled trials; bone morphogenetic protein; acute renal failure
• ISSN: 1046-6673; 1533-3450
• DOI: 10.1681/asn.2017020217

AKI after cardiac surgery is associated with mortality, prolonged hospital length of stay, use of dialysis, and subsequent CKD. We evaluated the effects of THR-184, a bone morphogenetic protein-7 agonist, in patients at high risk for AKI after cardiac surgery. We conducted a randomized, double-blind, placebo-controlled, multidose comparison of the safety and efficacy of perioperative THR-184 using a two-stage seamless adaptive design in 452 patients between 18 and 85 years of age who were scheduled for nonemergent cardiac surgery requiring cardiopulmonary bypass and had recognized risk factors for AKI. The primary efficacy end point was the proportion of patients who developed AKI according to Kidney Disease Improving Global Outcomes (KDIGO) criteria. The proportion of patients who developed AKI within 7 days of surgery was similar in THR-184 treatment groups and placebo groups (range, 74%-79%; =0.43). Prespecified secondary end point analysis did not show significant differences in the severity of AKI stage ( =0.53) or the total duration of AKI ( =0.44). A composite of death, dialysis, or sustained impaired renal function by day 30 after surgery did not differ between groups (range, 11%-20%; =0.46). Safety-related outcomes were similar across all treatment groups. In conclusion, compared with placebo, administration of perioperative THR-184 through a range of dose exposures failed to reduce the incidence, severity, or duration of AKI after cardiac surgery in high-risk patients.